Top

Published in:

Open Access 01-03-2010

Anabolic Therapies

Authors: Nancy E. Lane, Stuart L. Silverman

Published in: Current Osteoporosis Reports | Issue 1/2010

Abstract

The striking clinical benefits of intermittent parathyroid hormone in osteoporosis have begun a new era of skeletal anabolic agents. Recombinant human parathyroid hormone (rhPTH) (1–34) is the first US Food and Drug Administration–approved anabolic therapy. Its use has been limited by the need for subcutaneous injection. Newer delivery systems include transdermal and oral preparations. Newer anabolic therapies include monoclonal antibody to sclerostin, a potent inhibitor of osteoblastogenesis; and use of bone morphogenetic proteins and parathyroid hormone–related protein PTHrP, a calcium-regulating hormone similar to PTH.

van Amerongen R, Nusse R. Towards an integrated view of Wnt signaling in development. Development 2009;136:3205–14.CrossRefPubMed

Hoeppner LH, Secreto FJ, Westendorf JJ. Wnt signaling as a therapeutic target for bone diseases. Expert Opin Ther Targets 2009;13:455–96.CrossRef

Kneissel M. The promise of sclerostin inhibition for the treatment of osteoporosis. IBMS BoneKEy 2009;6:259–64.CrossRef

Balemans W, Ebeling M, Patel N, et al. Increased bone density in sclerostin is due to the deficiency of a novel secreted protein (SOST). Hum Mol Genet 2001;10:537–43.CrossRefPubMed

Wengenroth M, Vasvari G, Federspil PA, et al. Case 150: Van Buchem disease (hyperostosis corticalis generalisata). Radiology 209;253:272–76.

Li X, Ominsky MS, Nim QT, et al. Targeted deletion of sclerostin gene in mice results in increased bone formation and strength. J Bone Miner Res 2008;23:860–69.CrossRefPubMed

Li X, Ominsky MS, Warmingtom KS, et al. Sclerostin antibody treatment increases bone formation, bone mass and bone strength in a rat model of postmenopausal osteoporosis. J Bone Miner Res 2009;24:574–88.CrossRef

Baron R, Rowadi G. Targeting the Wnt/beta-catenin pathway to regulate bone formation in the adult skeleton. Endocrinology 2007;148:2635–43.CrossRefPubMed

Bellido T. Downregulation of SOST (sclerostin) by PTH: a novel mechanism of hormonal control of bone formation mediated by osteocytes. J Musculoskelet Neuronal Interact 2006;6:358–9.PubMed

10.

Lin C, Jiang X, Dai Z, et al. Sclerostin mediates bone response to mechanical unloading through antagonizing Wnt/beta-catenin signaling. J Bone Miner Res 2009;24:1651–61.CrossRefPubMed

11.

Schmidmaier G, Wildemann B. Perspectives: the role of BMPs in current orthopedic practice. IBMS BoneKEy 2009;6:244–53.CrossRef

12.

Govender S, Csimma C, Genant HK, et al. BMP-2 Evaluation in Surgery for Tibial Trauma (BESTT) Study Group. Recombinant human bone morphogenetic protein-2 for treatment of open tibial fractures: a prospective, controlled, randomized study of four hundred and fifty patients. J Bone Joint Surg Am 2002;84A:2123–34.

13.

Friedlander GE, Perry CR, Cole JD, et al. Osteogenic protein-1 (BMP-7) in treatment of tibial nonunions. J Bone Joint Surg Am 2001;83A(Suppl 1, Pt 2):S151–58.

14.

Burkus JK, Gornet MF, Dickman CA, Zdeblick TA. Anterior lumbar interbody fusion using rhBMP-2 with tapered interbody cages. J Spinal Disord Tech 2002;15:337–49.PubMed

15.

White AP, Vaccaro AR, Hall JA, et al. Clinical applications of BMP-7/OP-1 in fractures, nonunions and spinal fusion. Int Orthop 2007;31:735–41.CrossRefPubMed

16.

Coles CP, Gross M. Closed tibial shaft fractures: management and treatment complications. A review of the prospective literature. Can J Surg 2000;43:256–62.PubMed

17.

Chao EY, Inoue N. Biophysical stimulation of bone fracture repair, regeneration and remodeling. Eur Cell Mater 2003;6:72–84; discussion 84–85.PubMed

18.

Singh K, Smucker JD, Gill S, Boden SD. Use of recombinant human bone morphogenetic protein-2 as an adjunct in posterolateral lumbar spine fusion: a prospective CT-scan analysis at one and two years. J Spinal Disord Tech 2006;19:416–23.CrossRefPubMed

19.

Glassman SD, Dimar JR, Carreon LY, et al. Initial fusion rates with recombinant human bone morphogenetic protein-2/compression resistant matrix and a hydroxyapatite and tricalcium phosphate/collagen carrier in posterolateral spinal fusion. Spine 2005;30:1694–98.CrossRefPubMed

20.

Villavicencio AT, Burneikiene S, Nelson EL, et al. Safety of transforaminal lumbar interbody fusion and intervertebral recombinant human bone morphogenetic protein-2. J Neurosurg Spine 2005;3:436–43.CrossRefPubMed

21.

Vaccaro AR, Lawrence JP, Patel T, et al. The safety and efficacy of OP-1 (rhBMP-7) as a replacement for iliac crest autograft in posterolateral lumbar arthrodesis: a long-term (>4 years) pivotal study. Spine 2008;33:2850–62.CrossRefPubMed

22.

Poynton AR, Lane JM. Safety profile for the clinical use of bone morphogenetic proteins in the spine. Spine 2002;27(16 Suppl 1):S40–8.CrossRefPubMed

23.

Cosman F. Parathyroid hormone treatment of osteoporosis. Curr Opin Endocrinol Diabetes Obes 2008;15:495–501.PubMed

24.

Neer RM, Arnaud CD, Zanchetta JR, et al. Effect of parathyroid hormone (1–34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med 2001;344:1434–41.CrossRefPubMed

25.

•• Cosman F, Lane NE, Bolognese MA, et al. Effect of transdermal teriparatide administration on bone mineral density in postmenopausal women. J Clin Endocrin Metab 2009 Oct 26 [Epub ahead of print] This study demonstrates that the transdermal delivery of hPTH (1–34) was similar to the subcutaneous injection of hPTH (1–34) in terms of increase in BMD with no significant toxicity.

26.

Cormier M, Johnson B, Ameri M, et al. Transdermal delivery of desmopressin using coated microneedle array patch system. J Control Release 2004;97:503–511.PubMed

27.

Gopalakrishnan V, Hwang S, Loughrey H. Administration of ThPTH to humans using Macroflux transdermal technology results in the rapid delivery of biologically active PTH. J Bone Miner Res 2004;19(Suppl 1):S460.

28.

John MR, Haemmerle S, Launonen A, et al. A novel oral parathyroid hormone formulation, PTH134, demonstrated a potential therapeutically relevant pharmacokinetic and safety profile compared with teriparatide s.c. in healthy postmenopausal women after a single dose. Arthritis Rheum 2009;60(Suppl 1):S333.

29.

Stewart AF, Cain RL, Burr DB, et al. Six-month daily administration of parathyroid hormone and parathyroid hormone-related protein peptides to adult ovariectomized rats markedly enhances bone mass and biomechanical properties: a comparison of human parathyroid hormone 1–34, parathyroid hormone-related protein 1–36, and SDZ-parathyroid hormone 893. J Bone Miner Res 2000;15:1517–25.CrossRefPubMed

30.

Horwitz MJ, Tedesco MB, Garcia-Ocaña A, et al. Parathyroid hormone-related protein for the treatment of postmenopausal osteoporosis: defining the maximal tolerable dose. J Clin Endocrinol Metab 2010 Jan 8 [Epub ahead of print].

31.

Horwitz MJ, Tedesco MB, Gundberg C, et al. Short-term, high-dose parathyroid hormone-related protein as a skeletal anabolic agent for the treatment of postmenopausal osteoporosis. J Clin Endocrinol Metab 2003;88:569–75.CrossRefPubMed

Title: Anabolic Therapies
Authors: Nancy E. Lane
Stuart L. Silverman
Publication date: 01-03-2010
Publisher: Current Science Inc.
Published in: Current Osteoporosis Reports / Issue 1/2010
Print ISSN: 1544-1873
Electronic ISSN: 1544-2241
DOI: https://doi.org/10.1007/s11914-010-0005-4

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Anabolic Therapies

Abstract

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 1/2010

Orthopedic Uses of Teriparatide

The Role of Microbial Biofilms in Osteonecrosis of the Jaw Associated with Bisphosphonate Therapy

Denosumab Reduces the Incidence of New Vertebral Fractures in Men With Prostate Cancer

Glucocorticoid-Induced Osteoporosis: Management Update

Intravenous Zoledronic Acid: What Are the Indications for Male Osteoporosis?

Atypical Subtrochanteric and Femoral Shaft Fractures and Possible Association with Bisphosphonates